Scientific Updates

      Scientific Update June 2022 Issue 15

      PMI

      Published on
      Jun 9, 2022
      Topic
      Summary

      The 15th issue of the Scientific Update is co-edited by Manuel Peitsch, Prof., Chief Scientific Officer. It describes our commitment to advancing our ambition of achieving a smoke-free future for adults who would otherwise continue to smoke, the scientists working to make that goal a reality, and a look at the smoke-free products that we're building that future on.

      This issue on our transformation towards a smoke-free future examines our rigorous scientific assessment program and the work conducted by some of our scientists and R & D experts. This issue details the range of smoke-free products in our portfolio as we continue to leverage science and technology to develop, assess, and commercialize less harmful alternatives to cigarettes.

      Related Publications

      Use of capillary aerosol generator in continuous production of controlled aerosol for non-clinical studies

      Aerosol Physics Pre-clinical Toxicology

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels

      Clinical

      An in vitro evaluation of e-vapor products: The contributions of chemical adulteration, concentration, and device power

      Pre-clinical Toxicology

      Tobacco heating system has less impact on bone metabolism than cigarette smoke

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.